| 000 | 01919 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250517092748.0 | ||
| 264 | 0 | _c20180109 | |
| 008 | 201801s 0 0 eng d | ||
| 022 | _a1949-2553 | ||
| 024 | 7 |
_a10.18632/oncotarget.8943 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBraig, Friederike | |
| 245 | 0 | 0 |
_aLiquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma. _h[electronic resource] |
| 260 |
_bOncotarget _cJul 2016 |
||
| 300 |
_a42988-42995 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aCarcinoma, Squamous Cell _xdrug therapy |
| 650 | 0 | 4 | _aCell Line, Tumor |
| 650 | 0 | 4 |
_aCetuximab _xadministration & dosage |
| 650 | 0 | 4 |
_aDrug Resistance, Neoplasm _xgenetics |
| 650 | 0 | 4 |
_aErbB Receptors _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aFluorouracil _xadministration & dosage |
| 650 | 0 | 4 |
_aGTP Phosphohydrolases _xgenetics |
| 650 | 0 | 4 |
_aHead and Neck Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aHigh-Throughput Nucleotide Sequencing _xmethods |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLiquid Biopsy _xmethods |
| 650 | 0 | 4 |
_aMembrane Proteins _xgenetics |
| 650 | 0 | 4 |
_aMutation _xdrug effects |
| 650 | 0 | 4 |
_aPlatinum _xadministration & dosage |
| 650 | 0 | 4 |
_aProto-Oncogene Proteins p21(ras) _xgenetics |
| 650 | 0 | 4 |
_aras Proteins _xgenetics |
| 700 | 1 | _aVoigtlaender, Minna | |
| 700 | 1 | _aSchieferdecker, Aneta | |
| 700 | 1 | _aBusch, Chia-Jung | |
| 700 | 1 | _aLaban, Simon | |
| 700 | 1 | _aGrob, Tobias | |
| 700 | 1 | _aKriegs, Malte | |
| 700 | 1 | _aKnecht, Rainald | |
| 700 | 1 | _aBokemeyer, Carsten | |
| 700 | 1 | _aBinder, Mascha | |
| 773 | 0 |
_tOncotarget _gvol. 7 _gno. 28 _gp. 42988-42995 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.18632/oncotarget.8943 _zAvailable from publisher's website |
| 999 |
_c25963664 _d25963664 |
||